公司資料
Corcept 股價、新聞與催化劑
- 股票代碼:
- CORT
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
117.17 USD (+2.36%)
收盤價
最後更新: 2026年8月17日
7.64B USD
市值
股價為何變動
As of Aug 17, 2026, CORT closed up 2.36% at $117.17. No new same-company headline was identified in the current news window.
公司概覽
Cortisol Modulation Platform
Corcept Therapeutics develops medicines that selectively modulate the glucocorticoid receptor and the effects of cortisol. Its portfolio spans endocrinology, oncology, metabolism and neurology.
Cushing’s Syndrome Franchise
Corcept has an established commercial business treating hypercortisolism in patients with Cushing’s syndrome. Relacorilant has also completed the pivotal GRACE program, supporting the company’s effort to expand and modernize this endocrine franchise.
LIFYORLI in Ovarian Cancer
LIFYORLI, or relacorilant, is FDA approved with nab-paclitaxel for platinum-resistant ovarian cancer. The approval establishes Corcept’s first oncology product and validates cortisol modulation as a way to improve response to anticancer therapy.
Oncology Expansion
The BELLA program is evaluating relacorilant combinations in platinum-resistant and platinum-sensitive ovarian cancer and in previously treated endometrial cancer. These studies are intended to broaden use across gynecologic malignancies and treatment settings.
Metabolic and Neurologic Pipeline
Miricorilant is in the Phase 2b MONARCH trial for metabolic dysfunction-associated steatohepatitis. Dazucorilant is being prepared for Phase 3 testing in amyotrophic lateral sclerosis following a survival signal in the Phase 2 DAZALS study.
未來催化劑
- European decision on relacorilant plus nab-paclitaxel for platinum-resistant ovarian cancer expected by year-end 2026.
- BELLA Part A results expected by year-end 2026.
- Phase 2b MONARCH results for miricorilant in MASH expected by year-end 2026.
- Initiation of a Phase 3 dazucorilant trial in ALS planned later in 2026.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。